Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have been given an average rating of “Moderate Buy” by the twelve brokerages that are currently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $25.50.

KURA has been the subject of several research reports. Scotiabank decreased their price target on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a report on Wednesday, January 8th. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Kura Oncology in a research note on Thursday, February 27th. Cantor Fitzgerald upgraded Kura Oncology to a “strong-buy” rating in a research report on Tuesday, March 4th. JMP Securities restated a “market outperform” rating and set a $28.00 price objective on shares of Kura Oncology in a research report on Thursday, February 6th. Finally, UBS Group dropped their target price on Kura Oncology from $27.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, March 6th.

Kura Oncology Price Performance

Shares of KURA opened at $5.62 on Wednesday. Kura Oncology has a 52 week low of $5.41 and a 52 week high of $23.48. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The firm has a market cap of $453.84 million, a price-to-earnings ratio of -2.38 and a beta of 0.83. The stock has a 50 day moving average of $7.55 and a 200-day moving average of $11.19.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to analyst estimates of $57.96 million. As a group, analysts forecast that Kura Oncology will post -2.44 EPS for the current year.

Insider Transactions at Kura Oncology

In related news, SVP Thomas James Doyle sold 4,949 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the sale, the senior vice president now owns 88,193 shares of the company’s stock, valued at $694,078.91. The trade was a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares of the company’s stock, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 11,729 shares of company stock valued at $92,307. 5.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Kura Oncology

A number of hedge funds and other institutional investors have recently modified their holdings of KURA. FMR LLC grew its holdings in Kura Oncology by 26.1% during the third quarter. FMR LLC now owns 86,431 shares of the company’s stock worth $1,689,000 after acquiring an additional 17,913 shares during the period. BNP Paribas Financial Markets grew its stake in shares of Kura Oncology by 270.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 15,287 shares of the company’s stock worth $299,000 after purchasing an additional 11,158 shares during the last quarter. Jane Street Group LLC grew its stake in shares of Kura Oncology by 36.7% in the 3rd quarter. Jane Street Group LLC now owns 126,085 shares of the company’s stock worth $2,464,000 after purchasing an additional 33,848 shares during the last quarter. Barclays PLC raised its holdings in shares of Kura Oncology by 104.5% in the 3rd quarter. Barclays PLC now owns 165,484 shares of the company’s stock worth $3,234,000 after purchasing an additional 84,563 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Kura Oncology by 2.4% during the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company’s stock valued at $34,798,000 after purchasing an additional 41,535 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.